H
HILLEVAX INC
NASDAQ: HLVX (HilleVax, Inc.)
Last update: 1 hour ago2.06
-0.07 (-3.29%)
| Previous Close | 2.13 |
| Open | 2.13 |
| Volume | 54,513 |
| Avg. Volume (3M) | 297,725 |
| Market Cap | 103,207,440 |
| Price / Book | 0.710 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -2.15 |
| Total Debt/Equity (MRQ) | 15.93% |
| Current Ratio (MRQ) | 25.32 |
| Operating Cash Flow (TTM) | -88.51 M |
| Levered Free Cash Flow (TTM) | -49.51 M |
| Return on Assets (TTM) | -20.31% |
| Return on Equity (TTM) | -54.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | HilleVax, Inc. | Mixed | Mixed |
AIStockmoo Score
-1.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | -1.50 |
|
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 17.09% |
| % Held by Institutions | 70.85% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |